Brief Intervention to Reduce Fear of Public Speaking
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Anxiety, Healthy Studies, Psychiatric |
| Therapuetic Areas: | Psychiatry / Psychology, Other |
| Healthy: | No |
| Age Range: | 18 - 60 |
| Updated: | 4/5/2019 |
| Start Date: | June 2016 |
| End Date: | September 2020 |
The study will test the efficacy of propranolol or placebo, administered after retrieval of a
previously acquired public speaking fear, in reducing fear and avoidance of public speaking.
previously acquired public speaking fear, in reducing fear and avoidance of public speaking.
Twenty subjects with Performance-Only type of Social Anxiety Disorder will be enrolled in the
study. Participants will complete baseline assessments of fear and avoidance of public
speaking. Participants will be randomly assigned to a single dose of propranolol 40mg or
placebo, administered immediately after a fear activation procedure. Primary outcome
assessment will be self-reported fear of public speaking and avoidance behavior in a
behavioral avoidance task 2 weeks after the intervention.
study. Participants will complete baseline assessments of fear and avoidance of public
speaking. Participants will be randomly assigned to a single dose of propranolol 40mg or
placebo, administered immediately after a fear activation procedure. Primary outcome
assessment will be self-reported fear of public speaking and avoidance behavior in a
behavioral avoidance task 2 weeks after the intervention.
Inclusion Criteria:
- 18-60 years of age at the time of consent
- Principal Diagnosis of Social Anxiety Disorder, Performance only type
- Has clinically significant fear of public speaking
- Physically healthy
- If female, non-pregnant and not nursing
- Off all psychotropic drug for at least 4 weeks
- A level of understanding sufficient to provide written informed consent to all
required study tests and procedures.
Exclusion Criteria:
- History of other serious psychiatric disorder
- Current Major Depressive Disorder
- Presence of developmental disorder or intellectual disability
- SAD patients with SAD not of the performance only type
- Women who are pregnant or nursing
- Current use of psychiatric medication
- Current substance use disorder
- Persons planning to start another treatment during the study period.
- Any significant medical condition that might increase the risk or participation (e.g.,
seizure disorder, respiratory disorders [e.g., bronchial asthma], cardiovascular
disease [e.g., congestive heart failure, heart arrhythmias, sinus bradycardia and
greater than first degree block ], low blood pressure [ < 90/60], diabetes, liver or
kidney disorders)
- Use of medications that might negatively interact with propranolol (e.g., ACE
inhibitors; catecholamine depleting drugs, such as reserpine; calcium channel
blockers; digitalis glycosides; haloperidol; chlorpromazine; aluminum hydroxide gel;
phenytoin; phenobarbitone; rifampin; antipyrine; lidocaine; cimetidine; theophylline)
We found this trial at
1
site
Click here to add this to my saved trials
